ACE and hepatocellular carcinoma: Given that Sorafenib mainly inhibits HCC by targeting the tyrosine kinases ERK and MAPK, taken together with the involvement of DCP in these signaling cascades, we hypothesized that DCP might antagonize the efficacy of Sorafenib through activation of the Raf/MEK/ERK kinase cascade.